Cargando…
Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing
BACKGROUND: Regulatory approval of next generation sequencing (NGS) by the FDA is advancing the use of genomic-based precision medicine for the therapeutic management of cancer as standard care. Recent FDA guidance for the classification of genomic variants based on clinical evidence to aid clinicia...
Autores principales: | Dy, Grace K., Nesline, Mary K., Papanicolau-Sengos, Antonios, DePietro, Paul, LeVea, Charles M., Early, Amy, Chen, Hongbin, Grand’Maison, Anne, Boland, Patrick, Ernstoff, Marc S., Edge, Stephen, Akers, Stacey, Opyrchal, Mateusz, Chatta, Gurkamal, Odunsi, Kunle, Pabla, Sarabjot, Conroy, Jeffrey M., Glenn, Sean T., DeFedericis, Hanchun T., Burgher, Blake, Andreas, Jonathan, Giamo, Vincent, Qin, Maochun, Wang, Yirong, Kanehira, Kazunori, Lenzo, Felicia L., Frederick, Peter, Lele, Shashikant, Galluzzi, Lorenzo, Kuvshinoff, Boris, Morrison, Carl |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339275/ https://www.ncbi.nlm.nih.gov/pubmed/30658646 http://dx.doi.org/10.1186/s12911-019-0743-x |
Ejemplares similares
-
Oncologist uptake of comprehensive genomic profile guided targeted therapy
por: Nesline, Mary K., et al.
Publicado: (2019) -
Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay
por: Pabla, Sarabjot, et al.
Publicado: (2019) -
PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab
por: George, Saby, et al.
Publicado: (2018) -
Immune profiling and immunotherapeutic targets in pancreatic cancer
por: Lenzo, Felicia L., et al.
Publicado: (2021) -
A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors
por: Conroy, Jeffrey M., et al.
Publicado: (2021)